Destiny Pharma PLC
LSE:DEST
Intrinsic Value
Destiny Pharma Plc engages in the discovery, development and commercialization of new antimicrobial products. [ Read More ]
The intrinsic value of one DEST stock under the Base Case scenario is 5.06 GBX. Compared to the current market price of 19.25 GBX, Destiny Pharma PLC is Overvalued by 74%.
Valuation Backtest
Destiny Pharma PLC
Run backtest to discover the historical profit from buying and selling DEST stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Destiny Pharma PLC
Current Assets | 10.7m |
Cash & Short-Term Investments | 9.8m |
Receivables | 663.1k |
Other Current Assets | 176.8k |
Non-Current Assets | 2.4m |
PP&E | 21.6k |
Intangibles | 2.3m |
Current Liabilities | 1.1m |
Accounts Payable | 1.1m |
Earnings Waterfall
Destiny Pharma PLC
Revenue
|
0
GBP
|
Operating Expenses
|
-7.2m
GBP
|
Operating Income
|
-7.2m
GBP
|
Other Expenses
|
1.2m
GBP
|
Net Income
|
-6m
GBP
|
Free Cash Flow Analysis
Destiny Pharma PLC
What is Free Cash Flow?
DEST Profitability Score
Profitability Due Diligence
Destiny Pharma PLC's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Destiny Pharma PLC's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
DEST Solvency Score
Solvency Due Diligence
Destiny Pharma PLC's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Destiny Pharma PLC's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DEST Price Targets Summary
Destiny Pharma PLC
According to Wall Street analysts, the average 1-year price target for DEST is 62.22 GBX with a low forecast of 61.61 GBX and a high forecast of 64.05 GBX.
Shareholder Return
DEST Price
Destiny Pharma PLC
Average Annual Return | 4.32% |
Standard Deviation of Annual Returns | 59.63% |
Max Drawdown | -91% |
Market Capitalization | 18.3m GBX |
Shares Outstanding | 95 311 900 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Destiny Pharma Plc engages in the discovery, development and commercialization of new antimicrobial products. The company is headquartered in Brighton, Sussex. The company went IPO on 2017-09-04. The firm is engaged in the discovery, development, and commercialization of novel medicines with a focus on infection prevention. The company is focused on developing novel antimicrobial drug from its exeporfinium chloride platform and also from two biotherapeutic products. Its pipeline includes XF-73 nasal gel, NTCD-M3, and XF-73 dermal. XF-73 nasal gel is developed for the prevention of post-surgical staphylococcal infections. NTCD-M3, which is a naturally occurring non-toxigenic strain of C. difficile which lacks the genes that can express C. difficile toxins. NTCD-M3 is used for the prevention of C. difficile infection (CDI) recurrence. XF-73 derma is developed for the prevention and treatment of serious infections associated with wounds and ulcers such as diabetic foot ulcers (DFUs). The firm is co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections.
Contact
IPO
Employees
Officers
The intrinsic value of one DEST stock under the Base Case scenario is 5.06 GBX.
Compared to the current market price of 19.25 GBX, Destiny Pharma PLC is Overvalued by 74%.